Delayed-release Dimethyl Fumarate Demonstrated No Difference in Clinical Outcomes Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Real-World EFFECT Study (P1.362)

20183 citationsJournal Article

Authors

Jacob A. Sloane · Beth Israel Deaconess Medical Center

J. Theodore Phillips

Jonathan Calkwood

Anneke van der Walt · The Royal Melbourne Hospital

Jinny Min · Biogen (United States)

Fan Wu · Biogen (United States)

C. C. W. Taylor · Biogen (United States)

Abstract

To compare real-world effectiveness of delayed-release dimethyl fumarate (DMF) with fingolimod (FTY) in relapsing-remitting multiple sclerosis (RRMS) patients.

Topics & Keywords

Multiple Sclerosis Research Studies Mycobacterium research and diagnosis Acute Lymphoblastic Leukemia research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Neurology

Volume 90, Issue 15_supplement

DOI: 10.1212/wnl.90.15_supplement.p1.362

Field-Weighted Citation Impact: 0.49